Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on June 12, 2007
JNCI Journal of the National Cancer Institute 2007 99(12):975-976; doi:10.1093/jnci/djm008
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/12/975    most recent
djm008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Garfield, D. H.
Right arrow Articles by Davis, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garfield, D. H.
Right arrow Articles by Davis, P. J.
Related Collections
Right arrowRelated Article in JNCI
Right arrowResponse to this Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

CORRESPONDENCE

Re: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

David H. Garfield, Aleck Hercbergs, Paul J. Davis

Affiliations of authors: University of Colorado Health Sciences Center, Aurora, CO (DHG); Department of Radiation Oncology, The Cleveland Clinic, Cleveland, OH (AH); Ordway Research Institute, Inc, Albany, NY (PJD); Research Service, Stratton Veterans Affairs Medical Center, Albany, NY (PJD); Division of Molecular Medicine, Wadsworth Center, New York State Department of Health, Albany, NY (PJD)

Correspondence to: David H. Garfield, MD, 57 Hyde Park Circle, Denver, CO, 80209 (e-mail: david.garfield@earthlink.net).

The first 10% of the full text of this article appears below.

We wish to interject words of caution concerning Rini et al.'s conclusion (1) that "... replacement therapy should be undertaken as clinically indicated" in patients found to be hypothyroid while receiving sunitinib for renal cell carcinoma. We agree that moderately to severely symptomatic hypothyroid cancer patients require thyroid hormone replacement. However, we recommend . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Brian I. Rini, Ila Tamaskar, Phillip Shaheen, Renee Salas, Jorge Garcia, Laura Wood, Sethu Reddy, Robert Dreicer, and Ronald M. Bukowski
J Natl Cancer Inst 2007 99: 81-83. [Abstract] [Full Text] [PDF]

Response to this Correspondence

Response: Re: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Brian I. Rini
J Natl Cancer Inst 2007 99: 976-977. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
P Iglesias and J J Diez
Thyroid dysfunction and kidney disease
Eur. J. Endocrinol., April 1, 2009; 160(4): 503 - 515.
[Abstract] [Full Text] [PDF]